Astria Therapeutics (ATXS) Stock Price, News & Analysis

Company Overview

Astria Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles.

Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.

Key Stats

• Today's Range: $12.45 to $12.59
• 50-Day Range: $12.44 to $13.20
• 52-Week Range: $3.69 to $13.29
• Volume: 3.20 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $718.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Hold

Astria Therapeutics Stock Analysis - MarketRank™

Astria Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 771st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Astria Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 2 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Astria Therapeutics has a consensus price target of $24.50, representing about 94.8% upside from its current price of $12.58.

Amount of Analyst Coverage

Astria Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astria Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astria Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Astria Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATXS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astria Therapeutics does not currently pay a dividend.

Dividend Growth

Astria Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ATXS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.50% of the stock of Astria Therapeutics is held by insiders.

Percentage Held by Institutions

98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXS
• CIK: 1454789
• Web: www.catabasis.com
• Phone: (617) 349-1971
• Fax: 617-273-2637
• Employees: 30
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Astria Therapeutics: $24.50
• High Price Target: $49.00
• Low Price Target: $13.00
• Potential Upside/Downside: +94.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.26 million
• Net Margins: N/A
• Pretax Margin: -17,567.99%
• Return on Equity: -68.81%
• Return on Assets: -41.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.78
• Quick Ratio: 10.78

Sales & Book Value

• Annual Sales: $706 thousand
• Price / Sales: 1,017.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 3.17

Miscellaneous

• Outstanding Shares: 57,085,000
• Free Float: 54,516,000
• Market Cap: $718.13 million
• Optionable: Optionable
• Beta: 0.01